Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Zhang, Yizhuo ^a   Guo, Qing ^a   Zhao, Haifeng ^a   Zhao, Dandan ^b   Wu, Xiaoxiong ^b   Zhao, Weipeng ^a   Wang, Yafei ^a   Xia, Bing ^a   Da, Wanming ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CXCR4; Myelodysplastic syndrome; Prognostic factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; BIOLOGICAL MARKER; CXCR4 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; SURVIVAL TIME; BIOSYNTHESIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CXCR4; YOUNG ADULT;

EID: 84871188557     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0341-6     Document Type: Article

References (22)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
2. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer. 2008;113:1351-61.
3. Germing U, Hildebrandt B, Pfeilstocker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19:2223-31.
4. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27:754-62.
5. Bernasconi P, Klersy C, Boni M, et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol. 2007;137:193-205.
6. van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by f low cytometry. Blood. 2008;111:1067-77.
7. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25:1059-63.
8. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42:665-7.
9. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95:1668-74.
10. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094-6.
11. Kosmider O, Gelsi-Boyer V, Cheok M, et al. Groupe francophone des myelodysplasies. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285-91.
12. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14:171-9.
13. Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004;35:233-45.
14. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006;25(4):573-87.
15. Zhao BC, Wang ZJ, Mao WZ, et al. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol. 2011;17(19):2389-96.
16. Cabioglu N, Sahin A, Doucet M, et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis. 2005;22(1):39-46.
17. Kaifi JT, Yekebas EF, Schurr P, et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst. 2005;97(24):1840-7.
18. Anke C, Michael Lubbert M, William G, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109(2):786-91.
19. Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17(4):543-57.
20. Tormo M, Marugán I, Calabuig M. Myelodysplastic syndromes: an update on molecular pathology. Clin Transl Oncol. 2010;12(10):652-61.
21. Chunkang C, Rui Y, Feng X, et al. The roles of SDF-1/CXCR4 axis and its relationship with apoptosis in the myelodysplastic syndromes. Med Oncol. 2011;28(Suppl 1):S494-500.
22. Zhang Y, Zhao H, Zhao D, et al. SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis. Leuk Res. 2012;36(3):281-6.